---
title: "Outlook Therapeutics (OTLK) news: class action and going concern"
url: "https://aibio.space/companies/outlook-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "OTLK class action, going concern, offering and Nasdaq notice news: Outlook Therapeutics faces securities class action and stayed derivative suit over…"
---

OTLK Outlook Therapeutics, Inc. NASDAQ · United States

# Outlook Therapeutics (OTLK) news OTLK class action, going concern and offering news

Listings · 2026-09-25

## [Outlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval](https://aibio.space/news/outlook-therapeutics-gets-nasdaq-bid-price-notice-weeks-after-drugs/)

Nasdaq says OTLK closed under $1.00 for 30 straight business days. The company has until March 24, 2027 to cure, and its latest 10-Q carried a going-concern warning.

## Latest Outlook Therapeutics news

1. 2026-08-18 Legal [Outlook Therapeutics faces securities class action and stayed derivative suit over LYTENAVA BLA](https://aibio.space/news/outlook-therapeutics-faces-securities-class-action-stayed-derivative/) The New Jersey court dismissed the second amended complaint in part on Dec. 23, 2025, and plaintiffs refiled. Outlook and certain unnamed officers are defendants; a Delaware derivative suit is stayed.
2. 2026-08-17 Distress [Outlook Therapeutics files NT 10-Q for June quarter, cites finance staff turnover](https://aibio.space/news/outlook-therapeutics-files-nt-10-q-june-quarter-cites-finance-staff/) Outlook says it cannot file its quarterly report on time because of its size, finance department turnover and work on a public offering that closed on August 14, 2026. It has a going concern warning in its last annual report.
3. 2026-02-18 Listings [Outlook Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 17, 2026](https://aibio.space/news/outlook-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/) Nasdaq says Outlook's stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing, and a second 180-day period may be available.

## Outlook Therapeutics at a glance

- **Ticker**: OTLK

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $11.2 million

### Related companies

- [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) NASDAQ: LIMN
- [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) NASDAQ: ABVC
- [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR
- [Agentix](https://aibio.space/companies/agentix/) OTC: AGTX
- [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX
- [Avalo Therapeutics](https://aibio.space/companies/avalo-therapeutics/) NASDAQ: AVTX
- [Ardelyx](https://aibio.space/companies/ardelyx/) NASDAQ: ARDX
- [Innoviva](https://aibio.space/companies/innoviva/) NASDAQ: INVA

### Also on NASDAQ

- [Spectral AI](https://aibio.space/companies/spectral-ai/) MDAI
- [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) COYA
- [Pulmonx](https://aibio.space/companies/pulmonx/) LUNG
- [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) DFTX
- [LENSAR](https://aibio.space/companies/lensar/) LNSR
- [Nexalin Technology](https://aibio.space/companies/nexalin-technology/) NXL

## Outlook Therapeutics annual financials

| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | [$27.2 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) | [$41.8 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) |
| Net income (loss) | [-$62.4 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) | [-$75.4 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) |
| Cash from operations | [-$51.8 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) | [-$68.8 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) |
| Cash and equivalents | [$8.1 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/) | [$14.9 million](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Analysis

- Opinion Underperform Medium conviction 2026-10-28 [Outlook Therapeutics: Underperform. The approval is real, but the next raise comes first](https://aibio.space/analysis/outlook-therapeutics-fda-approval-balance-sheet/) LYTENAVA is approved and the market values it at about $97 million. We think Outlook must sell more stock at a discount before US sales can prove the launch, so we rate the shares Underperform.

Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/).

## Questions about Outlook Therapeutics

Is there a class action against Outlook Therapeutics?

Our latest story on this, dated Aug 18, 2026: "Outlook Therapeutics faces securities class action and stayed derivative suit over LYTENAVA BLA". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/outlook-therapeutics-faces-securities-class-action-stayed-derivative/).

Has Outlook Therapeutics issued a going-concern warning?

Our latest story on this, dated Sep 25, 2026: "Outlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/outlook-therapeutics-gets-nasdaq-bid-price-notice-weeks-after-drugs/).

Has Outlook Therapeutics raised money recently?

Our latest story on this, dated Aug 17, 2026: "Outlook Therapeutics files NT 10-Q for June quarter, cites finance staff turnover". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/outlook-therapeutics-files-nt-10-q-june-quarter-cites-finance-staff/).

Has Outlook Therapeutics received a Nasdaq deficiency notice?

Our latest story on this, dated Sep 25, 2026: "Outlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/outlook-therapeutics-gets-nasdaq-bid-price-notice-weeks-after-drugs/).

What is the ticker symbol of Outlook Therapeutics?

Outlook Therapeutics, Inc. trades under the ticker OTLK on NASDAQ.

Where is Outlook Therapeutics listed?

Outlook Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:41O; FWB:41O; GETTEX:41O; HAM:41O; HAN:41O; LS:A4046T; LSX:A4046T; MUN:41O; SWB:41O; TRADEGATE:41O; XETR:41O.

What is the SEC CIK of Outlook Therapeutics?

The SEC Central Index Key (CIK) for Outlook Therapeutics, Inc. is 1649989. Its filings are on SEC EDGAR.

How many shares does Outlook Therapeutics have outstanding?

243,447,554 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-18.

Which country or territory is Outlook Therapeutics listed under?

Our directory records Outlook Therapeutics, Inc. under United States.

What does Outlook Therapeutics do?

Our directory classifies Outlook Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Outlook Therapeutics?

The ISIN recorded for Outlook Therapeutics, Inc. is US69012T3059.

Does aibio.space cover Outlook Therapeutics?

aibio.space lists Outlook Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Outlook Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is Outlook Therapeutics profitable?

Outlook Therapeutics, Inc. reported a net loss of $62.4 million for the fiscal year ended Sep 30, 2025, and used $51.8 million of cash in operations, per its annual report to the SEC.

How much does Outlook Therapeutics spend on research and development?

$27.2 million in the fiscal year ended Sep 30, 2025, per its annual report.

## Investor discussion: Outlook Therapeutics

Members talk about Outlook Therapeutics (OTLK). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Outlook Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-09-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926112356/tm2626478d1_8k.htm)
2. 2026-08-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926097838/tm2623360d1_nt10q.htm)
3. 2026-08-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/tm2622399d2_8k.htm)
4. 2026-08-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/tm2622278d1_ex99-1.htm)
5. 2026-08-12 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926094970/tm2622281-1_424b5.htm)
6. 2026-07-16 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926084242/tm2620677d1_8k.htm)
7. 2026-06-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926078337/tm2619105d1_8k.htm)
8. 2026-06-01 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000114036126023583/ny20071594x2_def14a.htm)
9. 2026-05-28 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926067614/tm2615925d1_8k.htm)
10. 2026-05-22 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000114036126022627/ny20071594x1_pre14a.htm)
11. 2026-05-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926060305/tm2614480d1_8k.htm)
12. 2026-04-23 Financings Reported an unregistered sale of its securities. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926047242/tm2612510d1_424b5.htm)
13. 2026-02-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465926017118/tm266772d1_8k.htm)
14. 2025-12-19 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)
15. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465925052452/tm2516054d1_8k.htm)
16. 2025-05-22 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465925052010/tm2515210d2_424b5.htm)
17. 2025-03-14 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/otlk-20250311x8k.htm)
18. 2025-02-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465925010946/tm252313d6_def14a.htm)
19. 2025-01-31 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465925008146/tm254911d1_8k.htm)
20. 2025-01-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465925008169/tm252313-d4_pre14a.htm)
21. 2024-12-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm)
22. 2024-12-16 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1649989/000110465924128901/tm2431046d1_8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OTLK on TradingView](https://www.tradingview.com/symbols/NASDAQ-OTLK/).

## SEC filings and registration

- **SEC name**: Outlook Therapeutics, Inc.

- **CIK**: 1649989

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: OTLK (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: September 30

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 111 S. WOOD AVENUE, ISELIN, NJ, 08830

- **Phone**: 6096193990

- **Shares outstanding**: 243,447,554 as of 2026-08-14 (10-Q filed 2026-08-18)

- **Former names**: Oncobiologics, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926112356/tm2626478d1_8k.htm) filed 2026-09-30
- [8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm) filed 2026-09-18
- [8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926102446/tm2624167d1_8k.htm) filed 2026-08-27
- [10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm) filed 2026-08-18
- [8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/tm2622399d2_8k.htm) filed 2026-08-14
- [424B5](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_8k.htm) filed 2026-08-14
- [424B5](https://www.sec.gov/Archives/edgar/data/1649989/000110465926094970/tm2622281-1_424b5.htm) filed 2026-08-12

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001649989), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Outlook Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OTLK, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Outlook Therapeutics, Inc.

- **Ticker**: OTLK

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US69012T3059

- **Other listed symbols**: DUS:41O; FWB:41O; GETTEX:41O; HAM:41O; HAN:41O; LS:A4046T; LSX:A4046T; MUN:41O; SWB:41O; TRADEGATE:41O; XETR:41O

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OTLK/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/outlook-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Outlook Therapeutics (OTLK) news: class action and going concern", 2026-10-31, https://aibio.space/companies/outlook-therapeutics/